1119 related articles for article (PubMed ID: 19213682)
21. Evaluation of CCR5-Δ32 mutation among individuals with high risk behaviors, neonates born to HIV-1 infected mothers, HIV-1 infected individuals, and healthy people in an Iranian population.
Donyavi T; Bokharaei-Salim F; Nahand JS; Garshasbi S; Esghaei M; Sadeghi M; Jamshidi S; Khanaliha K
J Med Virol; 2020 Aug; 92(8):1158-1164. PubMed ID: 31854469
[TBL] [Abstract][Full Text] [Related]
22. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.
Tebas P; Stein D; Tang WW; Frank I; Wang SQ; Lee G; Spratt SK; Surosky RT; Giedlin MA; Nichol G; Holmes MC; Gregory PD; Ando DG; Kalos M; Collman RG; Binder-Scholl G; Plesa G; Hwang WT; Levine BL; June CH
N Engl J Med; 2014 Mar; 370(10):901-10. PubMed ID: 24597865
[TBL] [Abstract][Full Text] [Related]
23. The HIV type 1 coreceptor CCR5 and its role in viral transmission and disease progression.
Paxton WA; Kang S; Koup RA
AIDS Res Hum Retroviruses; 1998 Apr; 14 Suppl 1():S89-92. PubMed ID: 9581891
[TBL] [Abstract][Full Text] [Related]
24. Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.
Lathey JL; Tierney C; Chang SY; D'Aquila RT; Bettendorf DM; Alexander HC; Santini CD; Hughes AM; Barroga CF; Spector SA; Landes JE; Hammer SM; Katzenstein DA
J Infect Dis; 2001 Dec; 184(11):1402-11. PubMed ID: 11709782
[TBL] [Abstract][Full Text] [Related]
25. HIV-1-infected long-term slow progressors heterozygous for delta32-CCR5 show significantly lower plasma viral load than wild-type slow progressors.
Walli R; Reinhart B; Luckow B; Lederer E; Loch O; Malo A; Wank R; Schlöndorff D; Goebel FD
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul; 18(3):229-33. PubMed ID: 9665499
[TBL] [Abstract][Full Text] [Related]
26. Hematopoietic cell transplantation with cord blood for cure of HIV infections.
Petz LD; Redei I; Bryson Y; Regan D; Kurtzberg J; Shpall E; Gutman J; Querol S; Clark P; Tonai R; Santos S; Bravo A; Spellman S; Gragert L; Rossi J; Li S; Li H; Senitzer D; Zaia J; Rosenthal J; Forman S; Chow R
Biol Blood Marrow Transplant; 2013 Mar; 19(3):393-7. PubMed ID: 23089564
[TBL] [Abstract][Full Text] [Related]
27. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy.
O'Brien TR; McDermott DH; Ioannidis JP; Carrington M; Murphy PM; Havlir DV; Richman DD
AIDS; 2000 May; 14(7):821-6. PubMed ID: 10839590
[TBL] [Abstract][Full Text] [Related]
28. Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice.
Ye C; Wang W; Cheng L; Li G; Wen M; Wang Q; Zhang Q; Li D; Zhou P; Su L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881659
[TBL] [Abstract][Full Text] [Related]
29. TALENs-mediated homozygous CCR5Δ32 mutations endow CD4+ U87 cells with resistance against HIV‑1 infection.
Yu AQ; Ding Y; Lu ZY; Hao YZ; Teng ZP; Yan SR; Li DS; Zeng Y
Mol Med Rep; 2018 Jan; 17(1):243-249. PubMed ID: 29115572
[TBL] [Abstract][Full Text] [Related]
30. Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation.
Kordelas L; Verheyen J; Beelen DW; Horn PA; Heinold A; Kaiser R; Trenschel R; Schadendorf D; Dittmer U; Esser S;
N Engl J Med; 2014 Aug; 371(9):880-2. PubMed ID: 25162903
[No Abstract] [Full Text] [Related]
31. Prevalence of a 32 bp deletion in the gene for human immunodeficiency virus 1 co-receptor CCR5 in Slovak population.
Takácová M; Nogová P; Hábeková M; Staneková D
Acta Virol; 2008; 52(4):261-4. PubMed ID: 19143484
[TBL] [Abstract][Full Text] [Related]
32. CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy.
Allers K; Schneider T
Curr Opin Virol; 2015 Oct; 14():24-9. PubMed ID: 26143158
[TBL] [Abstract][Full Text] [Related]
33. MT-2 tropism and CCR-5 genotype strongly influence disease progression in HIV-1-infected individuals.
Bratt G; Leandersson AC; Albert J; Sandström E; Wahren B
AIDS; 1998 May; 12(7):729-36. PubMed ID: 9619804
[TBL] [Abstract][Full Text] [Related]
34. Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission.
Hladik F; Liu H; Speelmon E; Livingston-Rosanoff D; Wilson S; Sakchalathorn P; Hwangbo Y; Greene B; Zhu T; McElrath MJ
J Virol; 2005 Sep; 79(18):11677-84. PubMed ID: 16140745
[TBL] [Abstract][Full Text] [Related]
35. Phenotypic expressions of CCR5-delta32/delta32 homozygosity.
Nguyêñ GT; Carrington M; Beeler JA; Dean M; Aledort LM; Blatt PM; Cohen AR; DiMichele D; Eyster ME; Kessler CM; Konkle B; Leissinger C; Luban N; O'Brien SJ; Goedert JJ; O'Brien TR
J Acquir Immune Defic Syndr; 1999 Sep; 22(1):75-82. PubMed ID: 10534150
[TBL] [Abstract][Full Text] [Related]
36. Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and Δ32 heterozygote HIV-1-infected patient was not associated with functional cure.
Calin R; Fourati S; Schneider L; Gautheret-Dejean A; Lambert-Niclot S; Wirden M; Carcelain G; Katlama C; Marcelin AG; Tubiana R
J Antimicrob Chemother; 2015 Jan; 70(1):317-9. PubMed ID: 25239464
[No Abstract] [Full Text] [Related]
37. [HIV: vision of a cure].
Boffi el Amari E
Rev Med Suisse; 2011 Oct; 7(312):1968, 1970-3. PubMed ID: 22097447
[TBL] [Abstract][Full Text] [Related]
38. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors.
Cohen OJ; Vaccarezza M; Lam GK; Baird BF; Wildt K; Murphy PM; Zimmerman PA; Nutman TB; Fox CH; Hoover S; Adelsberger J; Baseler M; Arthos J; Davey RT; Dewar RL; Metcalf J; Schwartzentruber DJ; Orenstein JM; Buchbinder S; Saah AJ; Detels R; Phair J; Rinaldo C; Margolick JB; Pantaleo G; Fauci AS
J Clin Invest; 1997 Sep; 100(6):1581-9. PubMed ID: 9294127
[TBL] [Abstract][Full Text] [Related]
39. Frequencies of gene variant CCR5-Δ32 in 87 countries based on next-generation sequencing of 1.3 million individuals sampled from 3 national DKMS donor centers.
Solloch UV; Lang K; Lange V; Böhme I; Schmidt AH; Sauter J
Hum Immunol; 2017 Nov; 78(11-12):710-717. PubMed ID: 28987960
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant.
Salgado M; Kwon M; Gálvez C; Badiola J; Nijhuis M; Bandera A; Balsalobre P; Miralles P; Buño I; Martinez-Laperche C; Vilaplana C; Jurado M; Clotet B; Wensing A; Martinez-Picado J; Diez-Martin JL;
Ann Intern Med; 2018 Nov; 169(10):674-683. PubMed ID: 30326031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
